Citius Oncology, Stock Cash Flow From Operations
| CTOR Stock | 0.94 0.06 6.00% |
Citius Oncology, fundamentals help investors to digest information that contributes to Citius Oncology,'s financial success or failures. It also enables traders to predict the movement of Citius Stock. The fundamental analysis module provides a way to measure Citius Oncology,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Citius Oncology, stock.
Citius |
Citius Oncology, Company Cash Flow From Operations Analysis
Citius Oncology,'s Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Citius Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Citius Oncology, is extremely important. It helps to project a fair market value of Citius Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Citius Oncology,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Citius Oncology,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Citius Oncology,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Citius Oncology, has 0.0 in Cash Flow From Operations. This indicator is about the same for the Life Sciences Tools & Services average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Citius Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Oncology,'s direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics of similar companies.Citius Oncology, is currently under evaluation in cash flow from operations category among its peers.
Citius Fundamentals
| Current Valuation | 116.23 M | ||||
| Shares Outstanding | 2 M | ||||
| Number Of Shares Shorted | 39.42 K | ||||
| Price To Book | 4.55 X | ||||
| Market Capitalization | 116.23 M |
About Citius Oncology, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.